- Home
- JMIA vs RCUS Comparison
JMIA vs RCUS Comparison
Compare JMIA & RCUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JMIA
- RCUS
- Stock Information
- Founded
- JMIA 2012
- RCUS 2015
- Country
- JMIA Germany
- RCUS United States
- Employees
- JMIA N/A
- RCUS N/A
- Industry
- JMIA Catalog/Specialty Distribution
- RCUS Biotechnology: Pharmaceutical Preparations
- Sector
- JMIA Consumer Discretionary
- RCUS Health Care
- Exchange
- JMIA Nasdaq
- RCUS Nasdaq
- Market Cap
- JMIA 949.1M
- RCUS 906.4M
- IPO Year
- JMIA 2019
- RCUS 2018
- Fundamental
- Price
- JMIA $7.88
- RCUS $10.53
- Analyst Decision
- JMIA Hold
- RCUS Buy
- Analyst Count
- JMIA 1
- RCUS 8
- Target Price
- JMIA $4.75
- RCUS $20.71
- AVG Volume (30 Days)
- JMIA 5.6M
- RCUS 810.0K
- Earning Date
- JMIA 08-07-2025
- RCUS 08-06-2025
- Dividend Yield
- JMIA N/A
- RCUS N/A
- EPS Growth
- JMIA N/A
- RCUS N/A
- EPS
- JMIA N/A
- RCUS N/A
- Revenue
- JMIA $164,022,000.00
- RCUS $262,000,000.00
- Revenue This Year
- JMIA $8.75
- RCUS N/A
- Revenue Next Year
- JMIA $9.21
- RCUS $28.73
- P/E Ratio
- JMIA N/A
- RCUS N/A
- Revenue Growth
- JMIA N/A
- RCUS 6.07
- 52 Week Low
- JMIA $1.60
- RCUS $6.50
- 52 Week High
- JMIA $8.17
- RCUS $18.98
- Technical
- Relative Strength Index (RSI)
- JMIA 72.42
- RCUS 62.68
- Support Level
- JMIA $6.86
- RCUS $9.92
- Resistance Level
- JMIA $8.17
- RCUS $10.75
- Average True Range (ATR)
- JMIA 0.62
- RCUS 0.56
- MACD
- JMIA 0.09
- RCUS 0.08
- Stochastic Oscillator
- JMIA 91.83
- RCUS 77.83
About JMIA Jumia Technologies AG each representing two
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates majority of its revenue from the West Africa segment.
About RCUS Arcus Biosciences Inc.
Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.